About the Company
Oramed Pharmaceuticals, or Oramed (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ORMP News
Oramed Pharmaceuticals Inc ORMP
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Oramed Pharmaceuticals Inc. (ORMP) stock forecast and price target
Find the latest Oramed Pharmaceuticals Inc. ORMP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions ...
Oramed Pharmaceuticals Inc. Common Stock (ORMP)
*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...
Oramed Pharmaceuticals, Inc
Analysts say these cheap stocks have plenty of upside.
Oramed Pharmaceuticals Inc. Common Stock (ORMP)
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...
Oramed Pharmaceuticals Inc. (ORMP)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Oramed Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...